retatrutide phase 2 trial obesity nejm 2023 The that put “24%” on the map Triple hormone receptor agonist retatrutide

Since DHT causes follicle miniaturization in androgenetic alopecia, reducing it helps maintain existing hair

Further Reading References: (1) Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA

Furthermore, ZEB1 expression was significantly upregulated in stromal cells resistant to chemotherapy but appeared to be more susceptible to ferroptosis induced by statin treatment or GPX4 inhibition [7]

Regulatory status will remain contingent on new data and prevailing evidence standards, as well as the absence of approved therapeutic uses to date

Caroline Apovian, an obesity medicine specialist Massachusetts was among just 13 states whose Medicaid programs covered GLP-1s for weight loss at the beginning of 2026, according to the research organization KFF